InterMune, Inc. (ITMN) was a big mover last session, as its shares rose over 35% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock is now up above 60% in the past one-month timeframe.
In the last 30 days, the company witnessed nine negative estimate revisions and the Zacks Consensus Estimate also moved lower, signaling trouble down the road. So make sure to keep an eye on this stock going forward to see if yesterday’s move higher lasts.
InterMune currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Other better-ranked stocks in the biomedical/gene industry include Gilead Sciences Inc. (GILD), Cambrex Corporation. (CBM) and China Biologic Products, Inc. (CBPO). All three sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment